

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



和 鉑 醫 藥 控 股 有 限 公 司

HBM Holdings Limited

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 02142)

VOLUNTARY ANNOUNCEMENT CHINESE REGULATORY APPROVAL OF TWO IND APPLICATIONS FOR NEXT-GENERATION ANTI-CTLA-4 ANTIBODY HBM4003

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about its latest business updates.

The board of directors of the Company (the “**Board**”) is pleased to announce that, the National Medical Products Administration (國家藥品監督管理局) (the “**NMPA**”) of China has approved the Group’s Investigational New Drug (the “**IND**”) application for HBM4003, a next-generation, fully human anti-CTLA-4 monoclonal heavy chain only antibody in combination with programmed cell death protein 1 (“**PD-1**”) antibody in patients with advanced hepatocellular carcinoma (“**HCC**”) and other solid tumors, and IND application for HBM4003 in combination with PD-1 antibody in patients with advanced neuroendocrine tumor/neuroendocrine carcinoma (“**NET/NEC**”) and other solid tumors.

The Group has obtained an IND approval from the U.S. Food and Drug Administration and an IND approval from the NMPA in China, each for conducting a Phase I trial for HBM4003 as a monotherapy in advanced solid tumors. The Group has commenced ongoing Phase I study for HBM4003 monotherapy in Australia and in China and Phase I study for HBM4003 combination therapy in China.

About HBM4003

HBM4003 is the fully human anti-CTLA-4 monoclonal heavy chain only antibody (HCAb) generated from Harbour Mice®. By enhancing antibody-dependent cell cytotoxicity (ADCC) killing activity, HBM4003 has demonstrated significantly improved depletion specific to high CTLA-4 Treg cells in tumor tissues. The potent anti-tumor efficacy and differentiated pharmacokinetics with durable pharmacodynamic effect presents a favorable product profile. This novel and differentiated mechanism of action has the potential to improve efficacy while significantly reducing the toxicity of the drug in monotherapy and combo-therapy.

Cautionary Statement: We cannot guarantee that we will be able to develop, or ultimately market, HBM4003 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 10 September 2021

As at the date of this announcement, the board of directors of the Company comprises Dr. Jingsong Wang and Dr. Mai-Jing Liao as executive Directors; Mr. Yu Min Qiu, Mr. Junfeng Wang and Ms. Weiwei Chen as non-executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Mr. Ka Chi Yau as independent non-executive Directors.